Breaking Down Renhe Pharmacy Co., Ltd. Financial Health: Key Insights for Investors

Digest Renhe Pharmacy Co., Ltd.'s latest financial snapshot and decide whether its balance sheet and strategic moves merit a deeper look: in 2024 operating income fell to 4.075 billion yuan-a 19.02% year-over-year decline-and TTM revenue to June 30, 2025 dropped to 3.69 billion yuan, yet the market still valued the company at 8.09 billion yuan (Dec 12, 2025); profitability shows mixed signals with 2024 net income of 445.37 million yuan, a TTM net profit margin of 11.85% and EPS of 0.32 yuan, while operational strength appears in a 3.90 billion yuan net cash position, cash and short-term investments of 4.06 billion yuan, a robust Altman Z-Score of 7.2, and high liquidity ratios (current ratio 5.67, quick ratio 5.14); valuation metrics (trailing P/E 19.46, P/B 1.21, P/S 2.28, EV/EBITDA 8.28) sit alongside a 2.47% dividend yield with a 112.51% payout ratio, and risk/reward hinges on competition, regulatory shifts, raw-material volatility and planned growth initiatives-RWA platform partnership with IVD MEDICAL, expansion of online sales targeting an extra 10% market share by 2025, and a biotech collaboration forecast to add roughly 200 million yuan annually-read on for a chapter-by-chapter deep dive into revenue trends, margins, capital structure, liquidity and valuation.

Renhe Pharmacy Co., Ltd. (000650.SZ) - Revenue Analysis

Renhe Pharmacy's recent revenue trajectory shows notable contraction year-over-year with intermittent quarterly recovery. Key headline figures and drivers are summarized below.

• 2024 total operating income: ¥4.075 billion (-19.02% vs. 2023)
• TTM revenue ending 30 Jun 2025: ¥3.69 billion (-21.82% YoY)
• Q1-Q3 2025 operating revenue: ¥2.833 billion (-10.07% YoY)
• Q3 2025 quarterly revenue: ¥858.36 million (+9.16% YoY)
• Market capitalization (12 Dec 2025): ¥8.09 billion

Primary near-term pressure points include intensifying competition and market saturation in the pharmaceutical distribution and retail segments, which likely contributed to the annual revenue declines despite a positive Q3 2025 quarter.

• Drivers of decline: increased competition, market saturation, pricing pressure, and potential channel shifts (online vs. offline).
• Signs of stabilization: Q3 2025 YoY growth (+9.16%) suggests tactical or seasonal recovery.
• Investor signal: market cap of ¥8.09B on 12 Dec 2025 implies remaining market confidence despite revenue pressures.

For company positioning and strategic context, see: Mission Statement, Vision, & Core Values (2026) of Renhe Pharmacy Co., Ltd.

Renhe Pharmacy Co., Ltd. (000650.SZ) - Profitability Metrics

• Net income (2024): 445.37 million yuan (down 15.05% vs. 2023)
• Operating margin (Q2 2025): 21.08%
• Net profit margin (TTM ending 2025-06-30): 11.85% (decline year-over-year)
• Earnings per share (TTM ending 2025-06-30): 0.32 yuan
• Return on equity (ROE): 7.28%
• Gross margin: 36.70%

• Profitability drivers: a 36.70% gross margin and 21.08% operating margin point to effective cost control and pricing power in core operations.
• Pressure points: a 15.05% drop in 2024 net income and a declining TTM net profit margin (11.85%) reduce bottom-line momentum and EPS growth (0.32 CNY TTM).
• Capital efficiency: ROE at 7.28% indicates moderate returns on shareholder equity versus peers in the pharmaceutical/retail sector.

Renhe Pharmacy Co., Ltd. (000650.SZ) - Debt vs. Equity Structure

• Debt-to-equity ratio: 0.00 - indicates no long-term debt on the balance sheet.
• Total liabilities (Sept 2025): ¥1.06 billion - +34.51% year-over-year.
• Total equity (Sept 2025): ¥7.04 billion; book value per share: ¥4.48.
• Current ratio: 5.67 - strong short-term liquidity.
• Net cash position: ¥3.90 billion - sizeable cash buffer versus obligations.
• Interest coverage ratio: 3,855.49 - ample ability to meet interest expenses.

Renhe Pharmacy Co., Ltd. (000650.SZ) - Liquidity and Solvency

• Cash & short-term investments (Sept 2025): 4.06 billion yuan (+21.13% YoY)
• Operating cash flow (TTM to 30 Jun 2025): 867.98 million yuan
• Free cash flow (TTM to 30 Jun 2025): 716.64 million yuan
• Quick ratio: 5.14
• Effective tax rate: 26.65%
• Altman Z-Score: 7.2 (low bankruptcy risk)

Renhe Pharmacy Co., Ltd. (000650.SZ) - Valuation Analysis

Key market and valuation metrics for Renhe Pharmacy Co., Ltd. provide a snapshot of how the market prices the company relative to earnings, book value, sales and cash‑flow proxies. Below are the primary figures investors should weigh.

• Market capitalization: 8.40 billion yuan
• Enterprise value (EV): 5.19 billion yuan
• Trailing P/E: 19.46
• Price-to-book (P/B): 1.21
• Price-to-sales (P/S): 2.28
• EV/EBITDA: 8.28
• Dividend yield: 2.47%
• Payout ratio: 112.51%

For background on corporate structure, history and how the business operates, see Renhe Pharmacy Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Renhe Pharmacy Co., Ltd. (000650.SZ) - Risk Factors

• Regulatory and policy risks: drug approvals, pricing controls, and distribution rules in China can change rapidly and materially affect product availability and margins.
• Revenue pressure from competition: Renhe has shown recent revenue contraction driven by intensified retail and e‑commerce competition and market saturation in mature regions.
• Input cost volatility: fluctuations in raw material and API prices can compress gross margins, particularly for proprietary or less-differentiated SKUs.
• Healthcare policy shifts: reforms in reimbursement, essential medicines lists, or hospital procurement can change demand profiles for Renhe's products.
• Macroeconomic sensitivity: economic slowdowns reduce discretionary spending on OTC and wellness products, pressuring revenue and same‑store sales.
• Foreign-exchange exposure: imports of APIs or overseas procurement expose Renhe to CNY volatility versus USD/EUR, impacting costs and reported international revenues.

• Approval timelines and enforcement: delayed approvals or stricter GMP/enforcement can increase product time‑to‑market and CAPEX for compliance upgrades.
• Price controls and reimbursement adjustments can compress margins across patented and generic lines.

• Intense retail competition from national chains, regional players and online platforms (P2P and supermarkets expanding pharmacy counters) pressures pricing and market share.
• Store network maturity in core cities reduces organic growth potential; new growth requires either store conversions, acquisitions or digital channel expansion-each with execution risk.

• API and excipient price swings inflate COGS unpredictably; long procurement lead times raise inventory carrying costs and working capital needs.
• Dependency on imported APIs increases sensitivity to FX moves and trade frictions.

• Changes in public health policy, reimbursement packages or essential drug lists can quickly alter product demand patterns.
• Shifts toward centralized procurement or hospital channels reduce retail margins for certain therapeutic areas.

• Economic slowdowns reduce OTC and consumer-health spending, lowering same‑store sales and temporary promotions pressure.
• Currency depreciation against the USD/EUR raises costs of imported materials; about a modest portion of Renhe's cost base is FX‑exposed, amplifying margin variability in volatile FX regimes.

• Working capital strain: slower inventory turnover and rising payables increase borrowing needs-evident in the recent uptick in liabilities vs. cash balances.
• Leverage and refinancing: a debt/equity ratio near 0.85 requires monitoring if interest rates rise or credit markets tighten.

• Watch quarterly revenue and same‑store sales trends for signs of stabilization or continued decline.
• Track gross‑margin movements and COGS commentary for raw‑material inflation pass‑through or margin compression.
• Monitor regulatory announcements (pricing, procurement, reimbursement) and major policy updates affecting drug lists.
• Assess FX hedging disclosures and the share of imported inputs to gauge currency risk management.
• Review liquidity metrics (cash, operating cash flow, short‑term borrowings) to evaluate resilience to demand shocks.

Renhe Pharmacy Co., Ltd. (000650.SZ) Growth Opportunities

• RWA platform partnership: Renhe has partnered with IVD MEDICAL to establish an RWA trading platform in the U.S., positioning the firm to capture fees and service revenues from a market projected to reach $16 trillion by 2030.
• Online sales expansion: Management targets an additional 10% online market share by 2025 through marketplace growth, proprietary e-commerce upgrades, and digital marketing investments.
• Biotech collaboration: A collaboration with a leading biotech firm is expected to add ~200 million yuan in annual revenue once commercialized.
• Financial flexibility: A strong cash flow profile and a net cash position provide capital for M&A, platform investments, and scaling commercialization of new therapeutics.
• Diversified product mix: A broad portfolio spanning OTC, prescription generics, and specialty therapeutics reduces single-market exposure and supports cross-channel distribution.

• Revenue diversification: Serving OTC, hospital channels, retail pharmacies, and online marketplaces reduces single-channel dependency and smooths seasonality.
• Cash & leverage: Reported strong operating cash flow and a net cash position create optionality to finance the RWA platform and biotech programs without immediate dilution.
• Addressable markets: Beyond the $16T RWA outlook, growth in China's online pharmaceutical channel and specialty therapeutics offers multi-year tailwinds.